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Figure 1. Overall survival based on achievement of hematologic CR
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Treatment-related mortality (TRM), deﬁned as death occur-
ring within 100 days of SCT, was 9% (n¼52/607). Additionally,
there were 11 deaths during stem cell mobilization and
collection (SCMC). No death has occurred since 2005 during
SCMC and TRM has improved to 5% (n¼12/249). Total of 334
patients (55%) received melphalan at 200 mg/m2 and 273
(45%) received melphalan at 100-140 mg/m2 per protocol,
based upon age and organ function. Hematologic CR, as
deﬁned by international consensus criteria, occurred in 40%
(n¼204/512) of evaluable patients measured at 6-12 months
post SCT; by intention-to-treat the CR rate was 34%. Hema-
tologic CR occurred in 45% (n¼131/294) of patients who
received 200 mg/m2 of HDM compared to 33% (n¼73/218) of
patients who received 100-140 mg/m2 of HDM (X2 p¼0.02).
Hematologic relapse occurred in 40 patients (20%) with CR at
a median of 4 years (range, 1.6-12.4). The median OS is
6.7 years with a median follow-up of 4.5 years. The median
OS has not been reached for patients achieving a CR but
exceeds 12.8 years, compared to 6.0 years for those not
achieving CR (log-rank p<0.001). The median OS for patients
following hematologic relapse is 3.5 years. Twenty-ﬁve % of
patients are alive, up to 19 years after undergoing HDM/SCT.
These data highlight the remarkable long-term survival
obtained with HDM/SCT in AL amyloidosis. While survival is
strongly dependent upon achieving a hematologic CR, the
survival of patients who do not achieve a CR and of those
who relapse after CR also is notable, suggesting a beneﬁt of
treatment. Strategies to improve risk-stratiﬁcation of pa-
tients and reduce TRM, as well as using sequential or
combination therapies to increase the CR rate, will likely
improve outcomes in the future for patients who just a few
years ago were considered to have a rapidly fatal diagnosis.CLINICAL CELLULAR THERAPY41
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We have previously shown that small numbers of ex vivo-
expanded trivirus-speciﬁc T-cells (tVSTs) targeting EBV,
CMV, and Adv are safe, effective and protective in vivo.
However, broader implementation is limited by a
manufacturing process that is prolonged (8-12wks), complex
and requires infectious virus (EBV) and vector (Adv). More-
over, antigenic competition limits extension to additional
viruses. We have now made T-cell lines with activity against
5 common post-transplant viruses (EBV, CMV, Adv, BK,
HHV6), using a simpliﬁed 10-day procedure that excludes
viral components, and show that a single line can be clini-
cally effective against multiple viruses. With NHLBI-PACT
support 45 clinical-grade pentavalent (p)VSTs have been
generated. By exposing 30x106 PBMCs to overlapping
peptide libraries spanning Adv (Hexon, Penton), CMV (pp65,
IE1), EBV (LMP2, EBNA1, BZLF1), BK (Large T, VP1) and HHV6
(U11, U14, U90) antigens we expanded a median of 345x106
cells (range 99-825x106) over 9-11 days. The lines were
polyclonal, comprising both CD4+ (585%) and CD8+
(345%) cells, that expressed activation and memory
markers. pVST speciﬁcitywas dependent on the donor’s prior
viral exposure; 42/45 lines had Adv activity (Hexon:
453159; Penton: 367199 SFC/2x105), 24/45 against CMV
(IE1: 315135; pp65: 969442), 34/45 against EBV (LMP2:
14578; EBNA1: 11546; BZLF1: 10678), 24/45 against BK
(Large T: 13965; VP1: 22393) and 26/45 against HHV6
(U90: 11482; U11: 3817; U14: 9027). None of the lines
reacted against recipient cells. To date 11 allogeneic HSCT
recipients have received 0.5-2x107 pVSTs/m2 without
adverse events. Three patients received the cells prophylac-
tically and remained infection free up to 3 months post-
pVSTs. The other 8 patients were treated for one or more
active infections. Based on viral load measurements a single
infusion successfully controlled active infections associated
with all our targeted viruses: CMV (2 CR, 1 PR); EBV (4 CR,
including a frank PTLD case); Adv (1 CR); HHV6 (2 CR) and BK
(4 CR, 1 PR, 1 NR). Of note, all 3 patients with BK hemorrhagic
cystitis had marked improvement/disappearance of hema-
turia post-pVSTs. One subject had transient but severe
bladder pain with inﬂammation, seen on cytoscopy, and a
6-log fall in urine BK viral load with detection of BK-speciﬁc
T-cells in his bladder. Our only partially non-responding
patient had 3 viral infections (EBV, HHV6, BK) and cleared
EBV and HHV6 but not BK following the infusion of a line that
lacked speciﬁcity for this virus, likely reﬂecting the sero-
negative status of the donor. Thus, infusion of pVSTs has been
safe and clinically effective against up to four simultaneous/
sequential infections in a single HSCT recipient. We are
currently extending this platform to include other clinically
relevant viruses and are planning to assess the activity of “off
the shelf” 3rd party pVSTs for broader implementation.
